Bio-Rad(US:BIO)2025-07-31 21:00Q2 2025 Financial Performance - Revenue for Q2 2025 was $652 million, a 2.1% year-over-year increase, or 1.0% on a currency neutral basis[7,8] - GAAP gross margin was 53.0%, a decrease of 260 bps year-over-year[7] - Non-GAAP gross margin was 53.7%, a decrease of 270 bps year-over-year[8] - GAAP operating margin was 11.8%, a decrease of 410 bps year-over-year[7] - Non-GAAP operating margin was 13.6%, a decrease of 310 bps year-over-year[8] - Free cash flow was $71 million, an increase of $15 million year-over-year[8] Business Segment Performance - Life Science Group revenue was $263 million, a 4.9% year-over-year increase, or 3.8% on a currency neutral basis[14,15] - Clinical Diagnostics Group revenue was $389 million, a 0.2% year-over-year increase, or -0.7% on a currency neutral basis[17,18] Balance Sheet Highlights - Cash and short-term investments totaled $1374 million as of June 30, 2025[19] - Investment in Sartorius AG was $5156 million as of June 30, 2025[19] Full-Year 2025 Outlook (Currency Neutral YoY) - Revenue growth is expected to be between 0.0% and +1.0%[20] - Non-GAAP gross margin is expected to be between 53.5% and 54.5%[20] - Non-GAAP operating margin is expected to be between 12.0% and 13.0%[20] - Free cash flow is expected to be between $310 million and $330 million[20]